JP6371920B2 - 新規薬学組成物 - Google Patents
新規薬学組成物 Download PDFInfo
- Publication number
- JP6371920B2 JP6371920B2 JP2017555194A JP2017555194A JP6371920B2 JP 6371920 B2 JP6371920 B2 JP 6371920B2 JP 2017555194 A JP2017555194 A JP 2017555194A JP 2017555194 A JP2017555194 A JP 2017555194A JP 6371920 B2 JP6371920 B2 JP 6371920B2
- Authority
- JP
- Japan
- Prior art keywords
- alcohol
- aprepitant
- acid
- pharmaceutical composition
- capsule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Description
溶出液1:2.2%ラウリル硫酸ナトリウム(SLS)水溶液900mL
溶出液2:精製水900mL
溶出液3:水(pH6.8)900mL
0.2mol/Lリン酸水素カリウム250mLに0.2mol/L水酸化ナトリウム118mLを入れた後、水を入れて900mLとした。
溶出液4:酢酸塩緩衝液(pH4.0)900mL
0.05mol/L酢酸を0.05mol/L酢酸ナトリウムと41:9の割合で混合してpH4.0緩衝液を作った。
回転速度:2.2%SLS水溶液の場合100rpm
2.2%SLS水溶液以外の場合50rpm
Claims (12)
- アプレピタントまたはその薬学的に許容可能な塩と、
炭素数14ないし18個の脂肪酸、および炭素数14ないし18個の脂肪アルコールの中から選ばれた少なくとも一つの炭化水素誘導体と、
ポリオキシエチレン型非イオン性界面活性剤、ショ糖脂肪酸エステル、およびマクロゴール15ヒドロキシステアレートの中から選ばれた少なくとも一つの界面活性剤とを含む薬学組成物。 - 前記炭化水素誘導体と前記界面活性剤は、それぞれアプレピタントまたはその薬学的に許容可能な塩100重量部に対して、0.01〜500重量部の量で含有される請求項1に記載の薬学組成物。
- 前記界面活性剤は、顆粒状態の製剤形態である請求項1に記載の薬学組成物。
- 前記炭化水素誘導体と前記アプレピタントまたはその薬学的に許容可能な塩は、いずれも顆粒状態の製剤形態である請求項1に記載の薬学組成物。
- 前記炭化水素誘導体と前記アプレピタントまたはその薬学的に許容可能な塩は、いずれも固体分散体の状態である請求項1に記載の薬学組成物。
- 薬剤学的製剤の形態である請求項1に記載の薬学組成物。
- 前記薬剤学的製剤の形態は、カプセル剤または錠剤である請求項6に記載の薬学組成物。
- 前記カプセル剤は、前記界面活性剤を顆粒形態に内包し、前記炭化水素誘導体および前記アプレピタントまたはその薬学的に許容可能な塩をいずれも固体分散体の形態に内包する請求項7に記載の薬学組成物。
- 前記カプセル剤は、前記界面活性剤を顆粒形態に内包し、前記炭化水素誘導体および前記アプレピタントまたはその薬学的に許容可能な塩をいずれも顆粒形態に内包する請求項7に記載の薬学組成物。
- 前記脂肪酸は、ミリストレイン酸(myristoleic acid)、パルミトレイン酸(palmitoleic acid)、サピエン酸(sapienic acid)、オレイン酸(oleic aicd)、エライジン酸(elaidic acid)、バクセン酸(vaccenic acid)、リノール酸(linoleic acid)、リノエライジン酸(linoelaidic acid)、α−リノレン酸(α−linolenic acid)、ミリスチン酸(myristic acid)、パルミチン酸(palmitic acid)、およびステアリン酸(stearic acid)の中から選ばれた少なくとも一つである請求項1に記載の薬学組成物。
- 前記脂肪アルコールは、ミリスチルアルコール(myristyl alcohol)、ペンタデシルアルコール(pentadecyl alcohol)、セチルアルコール(cetyl alcohol)、パルミトレイルアルコール(palmitoleyl acohol)、ヘプタデシルアルコール(heptadecyl alcohol)、ステアリルアルコール(stearyl alcohol)、イソステアリルアルコール(isostearyl alcohol)、エライジルアルコール(elaidyl alcohol)、オレイルアルコール(oleyl alcohol)、リノレイルアルコール(linoleyl alcohol)、エライドリノレイルアルコール(elaidolinoleyl alcohol)、リノレニルアルコール(linolenyl alcohol)、エライドリノレニルアルコール(elaidolinolenyl alcohol)、リシノレイルアルコール(ricinoleyl alcohol)、およびセテアリルアルコール(cetearyl alcohol)の中から選ばれた少なくとも一つである請求項1に記載の薬学組成物。
- 前記ポリオキシエチレン型非イオン性界面活性剤は、ポリオキシエチレンソルビタン脂肪酸エステル(polyoxyethylene sorbitan fatty acid ester)、ポリオキシエチレンアルキルエーテル(polyoxyethylene alkyl ether)、及びポリオキシエチレンヒマシ油誘導体(polyoxyethylene castor oil derivative)の中から選ばれた少なくとも一つである請求項1に記載の薬学組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0006561 | 2015-01-14 | ||
KR1020150006561A KR101492572B1 (ko) | 2015-01-14 | 2015-01-14 | 신규 약학 조성물 |
PCT/KR2016/000398 WO2016114602A1 (en) | 2015-01-14 | 2016-01-14 | Novel pharmaceutical composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2018502154A JP2018502154A (ja) | 2018-01-25 |
JP6371920B2 true JP6371920B2 (ja) | 2018-08-08 |
Family
ID=52592018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017555194A Active JP6371920B2 (ja) | 2015-01-14 | 2016-01-14 | 新規薬学組成物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10058510B2 (ja) |
EP (1) | EP3244895B1 (ja) |
JP (1) | JP6371920B2 (ja) |
KR (1) | KR101492572B1 (ja) |
CN (1) | CN107205951B (ja) |
CA (1) | CA2972234C (ja) |
PH (1) | PH12017501081A1 (ja) |
WO (1) | WO2016114602A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018115888A1 (en) * | 2016-12-21 | 2018-06-28 | N4 Pharma Uk Limited | Novel formulations of aprepitant |
JP2019073445A (ja) * | 2017-10-12 | 2019-05-16 | 日本化薬株式会社 | アプレピタントを有効成分とする医薬組成物 |
CN109157516A (zh) * | 2018-11-05 | 2019-01-08 | 天津双硕医药科技有限公司 | 一种西洛他唑口服固体药物组合物 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5145682A (en) | 1986-05-30 | 1992-09-08 | Rutgers, The State University Of New Jersey | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration |
US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
UA76810C2 (uk) * | 2001-12-10 | 2006-09-15 | Мерк Енд Ко., Інк. | Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок |
EP1509209A1 (en) | 2002-05-23 | 2005-03-02 | UMD, Inc. | Compositions and method for transmucosal drug delivery and cryoprotection |
BR0315194A (pt) | 2002-10-31 | 2005-08-23 | Umd Inc | Composições terapêuticas para liberação de droga para a, e através da, cobertura epitelial |
US9227958B2 (en) | 2006-02-03 | 2016-01-05 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
EP2034952A4 (en) * | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | APREPITANT COMPOSITIONS |
WO2009108828A2 (en) * | 2008-02-27 | 2009-09-03 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
US20110224147A1 (en) * | 2008-08-01 | 2011-09-15 | Relevare Aust. Pyt. Ltd. | Methods and compositions |
CN102379845A (zh) | 2011-11-03 | 2012-03-21 | 南京优科生物医药有限公司 | 一种注射用阿瑞匹坦微乳剂及其制备方法 |
-
2015
- 2015-01-14 KR KR1020150006561A patent/KR101492572B1/ko active IP Right Grant
-
2016
- 2016-01-14 US US15/542,550 patent/US10058510B2/en active Active
- 2016-01-14 CA CA2972234A patent/CA2972234C/en active Active
- 2016-01-14 JP JP2017555194A patent/JP6371920B2/ja active Active
- 2016-01-14 CN CN201680005742.0A patent/CN107205951B/zh active Active
- 2016-01-14 EP EP16737566.6A patent/EP3244895B1/en active Active
- 2016-01-14 WO PCT/KR2016/000398 patent/WO2016114602A1/en active Application Filing
-
2017
- 2017-06-09 PH PH12017501081A patent/PH12017501081A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
PH12017501081B1 (en) | 2017-10-18 |
EP3244895A1 (en) | 2017-11-22 |
CA2972234A1 (en) | 2016-07-21 |
PH12017501081A1 (en) | 2017-10-18 |
EP3244895B1 (en) | 2019-03-06 |
KR101492572B1 (ko) | 2015-02-11 |
US20180000741A1 (en) | 2018-01-04 |
WO2016114602A9 (en) | 2016-10-06 |
WO2016114602A1 (en) | 2016-07-21 |
US10058510B2 (en) | 2018-08-28 |
CA2972234C (en) | 2019-01-08 |
CN107205951B (zh) | 2020-06-16 |
CN107205951A (zh) | 2017-09-26 |
EP3244895A4 (en) | 2018-07-25 |
JP2018502154A (ja) | 2018-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2325764T3 (es) | Preparaciones orales con buenas caracteristicas de desintegracion. | |
JP5794650B2 (ja) | 難溶性薬物の溶解性改善製剤 | |
US20080095838A1 (en) | Solid pharmaceutical composition containing a lipophilic active principle and preparation method thereof | |
JP2008534586A (ja) | フェノフィブレートの改良された製剤 | |
JP6371920B2 (ja) | 新規薬学組成物 | |
JP2018519279A (ja) | イリノテカン含有経口用固形製剤及びその製造方法 | |
US20230414578A1 (en) | Pharmaceutical composition | |
WO2019219823A1 (en) | Solid dispersion containing ritonavir | |
CA2966517C (en) | Solid oral formulation of fenretinide | |
CA2764172A1 (en) | A thrombin receptor antagonist and clopidogrel fixed dose tablet | |
JP2018508487A (ja) | デュタステリド含有固体分散体及びこれを含む組成物 | |
JP6391731B2 (ja) | フェノフィブラートのための強化された溶解速度を備えたウェーハ及びカプセル製剤 | |
KR102363727B1 (ko) | 생체이용률이 개선된 프란루카스트 함유 고형 제제의 조성물 및 그 제조방법 | |
JP2019073488A (ja) | アプレピタントを有効成分とする医薬錠剤 | |
EP2793856B1 (en) | Orally-disintegrating formulations of flurbiprofen | |
JP4993274B2 (ja) | フェノフィブラート含有製剤組成物の製造方法 | |
JP7115825B2 (ja) | エゼチミブ含有経口製剤及びその製造方法 | |
EP2175855A1 (en) | Stable pharmaceutical composition of a water-soluble vinorelbine salt | |
WO2020048449A1 (zh) | 包含1,3,5-三嗪衍生物或其盐的固体药物组合物 | |
JP2023508090A (ja) | ウチデロンの経口固形製剤 | |
WO2013100876A1 (en) | Risperidone formulations | |
WO2019221215A1 (ja) | ルビプロストン含有粒子状医薬組成物 | |
JPWO2007069675A1 (ja) | キサンチン誘導体の易吸収性経口製剤 | |
KR20070025070A (ko) | 시부트라민 및 계면활성제를 함유하는 고체분산체 및 그의제조방법 | |
KR20100009186A (ko) | 액상의 아세클로페낙을 함유하는 캡슐제 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170711 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180710 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180713 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6371920 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |